Publications by Professor Julie Irving - ePrints

Browsing publications by Professor Julie Irving.

Newcastle Authors	Title	Year
Dr Hayden Bell Dr Helen Blair Samantha Jepson Gosling Dr Martin Galler Dan Astley et al.	Combination p53 activation and BCL-x_L/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia	2024
Dr Dino Masic Dr Hayden Bell Dr Frederik van Delft Professor Julie Irving	Selection of dormant cells during treatment of T-lineage lymphoblastic leukemia and CREB as a therapeutic target	2024
Dr Jill Hunter Dr Elaine Willmore Professor Julie Irving Dr Stephany Veuger	Correction to: NF-kappa B mediates radio-sensitization by the PARP-1 inhibitor, AG-014699 (Oncogene, (2012), 31, 2, (251-264), 10.1038/onc.2011.229)	2023
Dr Richard Gallon Rachel Phelps Christine Hayes Dr Dino Masic Professor Julie Irving et al.	Detection of constitutional mismatch repair deficiency in children and adolescents with acute lymphoblastic leukemia	2023
Dr Dino Masic Kayleigh Fee Dr Hayden Bell Marian Case Juan Ojeda Garcia et al.	Hyperactive CREB subpopulations increase during therapy in pediatric B-lineage acute lymphoblastic leukemia	2023
Dr Hayden Bell Dr Helen Blair Mankaran Singh Professor Anthony Moorman Professor Olaf Heidenreich et al.	Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia	2023
Professor Julie Irving	Paediatric ambiguous lineage leukaemia with monocytic differentiation at diagnosis: case series and review of literature	2022
Dr Tobias Menne Professor Julie Irving Professor Ruth Plummer Dr Geoff Shenton Professor Gareth Veal et al.	Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial	2022
Professor Anthony Moorman Professor Julie Irving	Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials	2021
Dr Amir Enshaei Dr Sirintra Nakjang Lynne Minto Professor Julie Irving Beth Poole et al.	The genomic landscape of teenage and young adult T-cell acute lymphoblastic leukemia	2021
Marian Case Dr Dino Masic Dr David Jamieson Dr Frederik van Delft Professor Andrew Filby et al.	Label-Free Leukemia Monitoring by Computer Vision	2020
Liz Matheson Huw Thomas Marian Case Dr Helen Blair Rosanna Jackson et al.	Glucocorticoids and selumetinib are highly synergistic in RAS pathway mutated childhood acute lymphoblastic leukemia through upregulation of BIM	2019
Dr Rosanna Jackson Philip Berry Julie Errington Professor Julie Irving Professor Gareth Veal et al.	Impact of dose and duration of therapy on dexamethasone pharmacokinetics in childhood acute lymphoblastic leukaemia - a report from the UKALL 2011 trial	2019
Dr Lina Hamadeh Professor Julie Irving Professor Anthony Moorman	Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial	2019
Dr Paul Sinclair Dr Sarra Ryan Dr Matthew Bashton Shaun Hollern Rebecca Hanna et al.	SH2B3 inactivation through CN-LOH-12q is uniquely associated with B-cell precursor ALL with iAMP21 or other chromosome 21 gain	2019
Professor Julie Irving Professor Anthony Moorman	International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia	2018
Jean Norden Dr Kim Pearce Professor Julie Irving Professor Matthew Collin Professor Anne Dickinson et al.	The influence of glucocorticoid receptor single nucleotide polymorphisms on outcome after haematopoietic stem cell transplantation	2018
Professor Anthony Moorman Professor Julie Irving Professor James Allan Professor Christine Harrison FRCPath FMedSci	A genome-wide association study identifies risk loci for childhood acute lymphoblastic leukemia at 10q26.13 and 12q23.1	2017
Dr Britta Vormoor Professor Gareth Veal Melanie Griffin Professor Julie Irving Lynne Minto et al.	A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia	2017
Zach Dixon Dr Lindsay Nicholson Elizabeth Matheson Dr Paul Sinclair Professor Christine Harrison FRCPath FMedSci et al.	CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response	2017
Professor Julie Irving	Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia	2017
Professor Julie Irving	Acute lymphoblastic leukemia in the context of RASopathies	2016
Judith Weiland Dr Deepali Pal Marian Case Professor Julie Irving Dr Frida Ponthan et al.	BCP-ALL blasts are not dependent on CD19 expression for leukaemic maintenance	2016
Professor Julie Irving Dr Amir Enshaei Dr Amy Erhorn Lynne Minto Claire Schwab et al.	Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukaemia	2016
Rosanna Jackson Professor Julie Irving Professor Gareth Veal	Personalisation of dexamethasone therapy in childhood acute lymphoblastic leukaemia	2016
Dr Alex Elder Dr Klaus Rehe Dr Simon Bomken Dr Paul Sinclair Katie Dormon et al.	The ability to cross the blood-cerebrospinal fluid barrier is a generic property of acute lymphoblastic leukemia blasts.	2016
Professor Julie Irving	The Biology, Prognostic Relevance, and Targeted Treatment of Ras Pathway-Positive Childhood Acute Lymphoblastic Leukemia	2016
Dr Sarra Ryan Elizabeth Matheson Dr Paul Sinclair Dr Matthew Bashton Claire Schwab et al.	The role of the RAS pathway in iAMP21-ALL	2016
Professor Julie Irving	Towards an understanding of the biology and targeted treatment of paediatric relapsed acute lymphoblastic leukaemia	2016
Professor Julie Irving	Xenograft-directed personalized therapy for a patient with post-transplant relapse of ALL	2016
Professor Julie Irving Professor Anthony Moorman	Acute Leukemias of Ambiguous Lineage; Study on 247 Pediatric Patients	2015
Dr Klaus Rehe Dr Simon Bomken Dr Paul Sinclair Dr Lisa Russell Professor Olaf Heidenreich et al.	Childhood pre-B acute lymphoblastic leukaemia cells capable of central nervous system engraftment are common, heterogeneous and transit the blood-cerebrospinal fluid barrier	2015
Professor Anthony Moorman Professor Julie Irving Dr Amir Enshaei Dr Amy Erhorn Lynne Minto et al.	Composite Index for Risk Prediction in Relapsed Childhood Acute Lymphoblastic Leukaemia	2015
Zach Dixon Professor Julie Irving Dr Lindsay Nicholson	Crebbp K nockdown Does Not Impact on Glucocorticoid Induced Apoptosis in Childhood Acute Lymphoblastic Leukemia	2015
Zach Dixon Dr Lindsay Nicholson Professor Julie Irving	CREBBP Knockdown Does Not Impact on Glucocorticoid Induced Apoptosis in Childhood Acute Lymphoblastic Leukemia	2015
Dr Sarah Fordham Mike Cole Professor Julie Irving Professor James Allan	Cytarabine preferentially induces mutation at specific sequences in the genome which are identifiable in relapsed acute myeloid leukaemia	2015
Dr Lindsay Nicholson Dr Emily Mavin Lynne Minto Professor Julie Irving Professor Anne Dickinson et al.	Gene Expression Profiling Implicates Attenuation of NFkB Signalling By Regulatory T Cells in Modulating Dendritic Cell Function	2015
Dr Lindsay Nicholson Dr Emily Mavin Lynne Minto Professor Julie Irving Professor Anne Dickinson et al.	Gene Expression Profiling Implicates Attenuation of NFkB Signalling By Regulatory T Cells in Modulating Dendritic Cell Function	2015
Dr Lindsay Nicholson Elizabeth Matheson Lynne Minto Christopher Keilty Maryna Sanichar et al.	Quantitative proteomic analysis reveals maturation as a mechanism underlying glucocorticoid resistance in B lineage ALL and re-sensitization by JNK inhibition	2015
Professor Julie Irving Elizabeth Matheson Helen Blair Marian Case Isabella Swidenbank et al.	Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood. 2014;124(23):3420-3430	2015
Professor Anthony Moorman Professor Julie Irving Professor James Allan Professor Christine Harrison FRCPath FMedSci	The 9p21.3 risk of childhood acute lymphoblastic leukaemia is explained by a rare high-impact variant in CDKN2A	2015
Dr Jeyanthy Eswaran Dr Paul Sinclair Professor Olaf Heidenreich Professor Julie Irving Dr Lisa Russell et al.	The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia	2015
Dr Sarah Fordham Mike Cole Professor Julie Irving Professor James Allan	Cytarabine leaves a mutational fingerprint in relapsing leukemia	2014
Professor Julie Irving Elizabeth Matheson Dr Helen Blair Marian Case Isabella Swidenbank et al.	Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition	2014
Dr Thomas Knight Professor Julie Irving	Ras/Raf/MEK/ERK pathway activation in childhood acute lymphoblastic leukemia and its therapeutic targeting	2014
Dr Klaus Rehe Kerrie Wilson Dr Simon Bomken Dr Daniel Williamson Professor Julie Irving et al.	Acute B lymphoblastic leukaemia-propagating cells are present at high frequency in diverse lymphoblast populations	2013
Professor Graham Jackson Professor Julie Irving Professor James Allan	Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk	2013
Professor Julie Irving Professor James Allan	Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype	2013
Dr Lindsay Nicholson Elizabeth Matheson Lynne Minto Marian Case Maryna Sanichar et al.	Casitas B lymphoma mutations in childhood acute lymphoblastic leukemia	2012
Professor Julie Irving Professor James Allan	Common genetic variation contributes significantly to the risk of childhood B-cell precursor acute lymphoblastic leukemia	2012
Professor Julie Irving	Detection and monitoring of normal and leukemic cell populations with hierarchical clustering of flow cytometry data	2012
Dr Jill Hunter Dr Elaine Willmore Professor Julie Irving Dr Stephany Veuger Professor barbara Durkacz et al.	NF-kappa B mediates radio-sensitization by the PARP-1 inhibitor, AG-014699	2012
Michael Batey Dr Yan Zhao Dr Helen Maitland Professor Hing Leung Dr Andrew Hall et al.	Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma	2011
Professor Julie Irving Professor James Allan	DNA mismatch repair status affects cellular response to Ara-C and other anti-leukemic nucleoside analogs	2011
Dr Vikki Rand Dr Lisa Russell Claire Schwab Hannah Ensor Professor Julie Irving et al.	Genomic characterization implicates iAMP21 as a likely primary genetic event in childhood B-cell precursor acute lymphoblastic leukemia	2011
Haya AL-Balool Dr Mark Wade Dr Jonathan Coxhead Professor Julie Irving Professor David Elliott et al.	Post-transcriptional exon shuffling events in humans can be evolutionarily conserved and abundant	2011
Michael Batey Professor Julie Irving Professor Herbie Newell	Potent, Selective Inhibitors of Fibroblast Growth Factor Receptor Define Fibroblast Growth Factor Dependence in Preclinical Cancer Models	2011
Dr Lindsay Nicholson Charlotte Evans Elizabeth Matheson Lynne Minto Christopher Keilty et al.	Quantitative Proteomic Analysis Reveals Maturation As a Mechanism Underlying Glucocorticoid Resistance in Childhood Acute Lymphoblastic Leukemia and PAX5 As a Re-Sensitising Therapeutic Target	2011
Dr Sarra Ryan Dr Vikki Rand Claire Schwab Heather Morrison Elizabeth Matheson et al.	Ras Signalling Pathway and Novel Target Genes Related to Down Syndrome Contribute to the Development of B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) in iAMP21 Patients	2011
Professor Graham Jackson Dr Nicola Sunter Dr Andrew Hall Professor Julie Irving Professor James Allan et al.	A polymorphism in the 3' UTR of IRF4 linked to susceptibility and pathogenesis in chronic lymphocytic leukaemia and Hodgkin lymphoma has limited impact in multiple myeloma	2010
Dr Amy Peasland Elizabeth Matheson Dr Andrew Hall Professor Julie Irving	Alternative splicing of hMLH1 in childhood acute lymphoblastic leukaemia and characterisation of the variably expressed Δ9/10 isoform as a dominant negative species	2010
Professor Julie Irving	Analysis of BCR ABL1 Tyrosine Kinase Domain Mutations In Primitive Chronic Myeloid Leukemia Cells Identifies a Unique Mutator Phenotype	2010
Professor Julie Irving	Analysis of BCR-ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype	2010
Professor Stephen O'Brien Professor Julie Irving	Analysis of BCR-ABL1 Tyrosine Kinase Domain Mutations In Primitive Chronic Myeloid Leukemia Cells Identifies a Unique Mutator Phenotype	2010
Professor Julie Irving Professor James Allan	Cellular Response to Cytarabine Is Modulated by the DNA Mismatch Repair Pathway: Implications for Treatment of Acute Myeloid Leukemia	2010
Dr Sarah Fordham Emeritus Professor Keith Scott Professor Julie Irving Professor James Allan	Cellular Response to Cytarabine is Modulated by the DNA Mismatch Repair Pathway: Implications for Treatment of Acute Myeloid Leukemia	2010
Professor Julie Irving Professor James Allan	Genome-wide homozygosity signatures and childhood acute lymphoblastic leukemia risk	2010
Dr Klaus Rehe Kerrie Wilson Dr Simon Bomken Hesta McNeill Professor Julie Irving et al.	In Acute Lymphoblastic Leukaemia, Stemness Is Frequent and Ubiquitous	2010
Dr Klaus Rehe Kerrie Wilson Dr Simon Bomken Hesta McNeill Professor Julie Irving et al.	In Acute Lymphoblastic Leukaemia, Sternness Is Frequent and Ubiquitous	2010
Dr Klaus Rehe Kerrie Wilson Dr Simon Bomken Hesta McNeill Professor Julie Irving et al.	In acute lymphoblastic leukemia, stemness is frequent and ubiquitous	2010
Dr Klaus Rehe Kerrie Wilson Hesta McNeill Professor Julie Irving Professor Hermann Josef Vormoor et al.	In standard and high risk acute lymphoblastic leukemias disease propagating cells are abundant and not confined to certain immunophenotypic fractions	2010
Professor Julie Irving Professor James Allan	MHC variation and risk of childhood B-cell precursor acute lymphoblastic leukaemia	2010
Elizabeth Matheson Lynne Minto Dr Andrew Hall Professor Julie Irving	Mismatch repair and the downstream target genes, PAX5 and Ikaros, in childhood acute lymphoblastic leukemia	2010
Dr Lindsay Nicholson Dr Andrew Hall Dr Chris Redfern Professor Julie Irving	NF kappa B modulators in a model of glucocorticoid resistant, childhood acute lymphoblastic leukemia	2010
Professor Julie Irving Professor James Allan Professor Anthony Moorman Professor Christine Harrison FRCPath FMedSci	Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk	2010
Sarina Sulong Professor Anthony Moorman Professor Julie Irving Marian Case Professor Simon Bailey et al.	A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroups	2009
Dr Lisa Russell Professor Olaf Heidenreich Professor Julie Irving Professor Anthony Moorman Heather Morrison et al.	Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia	2009
Professor Julie Irving Marian Case Lynne Minto Sally Lawson	Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting	2009
Kate Wilson Marian Case Lynne Minto Professor Simon Bailey Dr Nicholas Bown et al.	Flow minimal residue disease monitoring of candidate leukemic stem cells defined by the immunophenotype, CD34⁺CD38^lowCD19⁺ in B-lineage childhoood acute lymphoblastic leukemia	2009
Professor Julie Irving	Levels of glucocorticoid receptor and its ligand determine sensitivity and kinetics of glucocorticoid-induced leukemia apoptosis	2009
Professor Julie Irving Professor James Allan	Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia	2009
Professor Anthony Moorman Dr Michael Griffiths Professor Julie Irving Professor Christine Harrison FRCPath FMedSci	Methylation of tumour suppressor gene promoters in the presence and absence of transcriptional silencing in high hyperdiploid acute lymphoblastic leukaemia	2009
Nicola Brown Professor Julie Irving	MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells	2009
Dr Lindsay Nicholson Elizabeth Matheson Lynne Minto Christopher Keilty Dr Andrew Hall et al.	Quantitative Proteomic Analysis Implicates An Altered B-Cell Differentiation State as a Mechanism Underlying GC-Resistance in An Acute Lymphoblastic Leukaemia (ALL) Cell Line Model	2009
Dr Vikki Rand Dr Lisa Russell Professor Julie Irving Lisa Jones Dr Dino Masic et al.	What Is the Initiating Mechanism of iAMP21 in Childhood B Cell Precursor ALL?	2009
Dr Akheel Syed Dr Christina Halpin Professor Julie Irving Professor Nigel Unwin Professor Martin White et al.	A common intron 2 polymorphism of the glucocorticoid receptor gene is associated with insulin resistance in men	2008
Michael Batey Dr Amy Peasland Professor Julie Irving Professor Herbie Newell	Development of inhibitors of the fibroblast growth factor receptor (FGFR) kinase using a fragment based approach	2008
Professor Julie Irving Lynne Minto Dr Andrew Hall	Genomic analysis of different clonal evolution in a twin pair with t(12;21) positive acute lymphoblastic leukemia sharing the same prenatal clone [8]	2008
Elizabeth Matheson Lynne Minto Professor Anthony Moorman Dr Andrew Hall Professor Julie Irving et al.	Heterogeneous breakpoints target PAX5 in acute lymphoblastic leukaemia patients with dicentric chromosomes	2008
Dr Simon Bomken Kerrie Wilson Professor Julie Irving Professor Hermann Josef Vormoor	In Childhood Acute Lymphoblastic Leukemia, Blasts at Different Stages of Immunophenotypic Maturation Have Stem Cell Properties	2008
Kerrie Wilson Dr Klaus Rehe Dr Simon Bomken Marian Case Professor Julie Irving et al.	In Childhood ALL, Both Blasts with a CD20(-/Low) and a CD20(High) Immunophenotype, Have the Ability to Transfer the Leukemia Onto Immune-Deficient NOD/Scid Y-/- Mice	2008
Michael Batey Dr Helen Maitland Professor Hing Leung Dr Andrew Hall Professor Graham Jackson et al.	In vitro activity of the multi targeted receptor tyrosine kinase inhibitor sunitinib against multiple myeloma cell lines is not predictive of in vivo xenograft response	2008
Professor Anthony Moorman Sarina Sulong Professor Julie Irving Marian Case Lynne Minto et al.	Inactivation of CDKN2A in childhood acute lymphoblastic leukaemia (ALL) occurs principally by deletion and is strongly correlated with cytogenetic subgroups	2008
Dr Karel Fiser Professor Julie Irving Professor Hermann Josef Vormoor	MRD Monitoring of Childhood ALL Using Hierarchical Clustering and Support Vector Machine Learning of Complex Multi-Parameter Flow Cytometry Data	2008
Marian Case Elizabeth Matheson Lynne Minto Dr Nicholas Bown Professor Simon Bailey et al.	Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia	2008
Marian Case Elizabeth Matheson Lynne Minto Professor Christine Harrison FRCPath FMedSci Dr Nicholas Bown et al.	Somatic mutation of genes impacting on the RAS-RAF-MEK-ERK pathway is the most common genetic abnormality in childhood acute lymphoblastic leukaemia, is implicated in disease progression and provides a rationale for therapeutic targeting	2008
Kerrie Wilson Marian Case Lynne Minto Professor Simon Bailey Professor Hermann Josef Vormoor et al.	The CD34⁺ CD38^Low CD19⁺ Candidate Leukemic Stem Cell Phenotype Revisited: Useful for Flow MRD Monitoring?	2008
Marian Case Dr Tina Davies Professor Anthony Moorman Dr Andrew Hall Professor Julie Irving et al.	The complex genomic profile of ETV6-RUNX1 positive acute lymphoblastic leukemia highlights a recurrent deletion of TBL1XR1	2008
Elizabeth Matheson Professor Anthony Moorman Dr Andrew Hall Professor Christine Harrison FRCPath FMedSci Professor Julie Irving et al.	Variable breakpoints target PAX5 in patients with dicentric chromosomes: A model for the basis of unbalanced translocations in cancer	2008
Elizabeth Matheson Dr Linda Hogarth Marian Case Professor Julie Irving Dr Andrew Hall et al.	DHFR and MSH3 co-amplification in childhood acute lymphoblastic leukaemia, in vitro and in vivo	2007
Professor Anthony Moorman Marian Case Professor Julie Irving Dr Andrew Hall Professor Christine Harrison FRCPath FMedSci et al.	Genomic profiling reveals multiple genetic targets in ETV6-RUNX1 positive acute lymphoblastic leukaemia (ALL)	2007
Adillah Binti Yusof Professor Julie Irving Marian Case Lynne Minto Professor Christine Harrison FRCPath FMedSci et al.	Red blood cell alloimmunization is affected by depletion of donor white cell subsets	2007
Elizabeth Matheson Lynne Minto Professor Anthony Moorman Dr Andrew Hall Professor Julie Irving et al.	Variable Breakpoints Target PAX5 in Patients with Dicentric Chromosomes: A Model for the Basis of Unbalanced Translocations in Cancer	2007
Dr Andrew Hall Sarina Sulong Professor Christine Harrison FRCPath FMedSci Lynne Minto Dr Nicholas Bown et al.	Assessment of aneuploidy in childhood acute lymphoblastic leukaemia using high density oligonucleotide arrays.	2006
Dr Akheel Syed Professor Julie Irving Dr Chris Redfern Dr Andrew Hall Professor Nigel Unwin et al.	Association of glucocorticoid receptor polymorphism A3669G in exon 9β with reduced central adiposity in women	2006
Sarina Sulong Professor Julie Irving Marian Case Lynne Minto Dr Nicholas Bown et al.	Comprehensive analysis of p16(INK4a) in childhood acute lymphoblastic leukemia reveals homozygous deletion, haploinsufficiency and acquired isodisomy at the 9p locus with intact p16(INK4a).	2006
Professor Julie Irving Lynne Minto Elizabeth Matheson Dr Lindsay Nicholson Dr Andrew Hall et al.	Glucocorticoid resistance in two key models of acute lymphoblastic leukemia occurs at the level of the glucocorticoid receptor	2006
Professor Julie Irving Lynne Minto Elizabeth Matheson Marian Case Professor Simon Bailey et al.	Mutation in genes impacting on the RAS-RAF-MEK-ERK pathway are found at high incidence in childhood acute lymphoblastic leukemia at both diagnosis and at relapse.	2006
Dr Andrew Hall Professor Julie Irving Lynne Minto	Reply to 'ATM variants and predisposition to childhood T-lineage acute lymphoblastic leukaemia' by Gumy-Pause et al. [6]	2006
Professor Julie Irving Dr Andrew Hall	Constitutional segmental uniparental disomy in a twin pair with t(12;21) positive acute lymphoblastic leukemia characterized by the same prenatal clone and divergent clonal evolution	2005
Dr Mark Velangi Elizabeth Matheson Dr Andrew Hall Professor Julie Irving	Detecting mismatch repair defects in myeloma	2005
Professor Julie Irving Lynne Minto Professor Simon Bailey Dr Andrew Hall	Loss of heterozygosity and somatic mutations of the Glucocorticoid receptor gene are rarely found at relapse in pediatric acute lymphoblastic leukemia but may occur in a subpopulation early in the disease course	2005
Professor Julie Irving Clare Bloodworth Dr Nicholas Bown Marian Case Dr Linda Hogarth et al.	Loss of heterozygosity in childhood acute lymphoblastic leukemia detected by genome-wide microarray single nucleotide polymorphism analysis	2005
Dr Andrew Hall Professor Julie Irving Lynne Minto	Relation between genetic variants of the ataxia telangiectasia-mutated (ATM) gene, drug resistance, clinical outcome and predisposition to childhood T-lineage acute lymphoblastic leukaemia	2005
Sarina Sulong Marian Case Lynne Minto Dr Bridget Wilkins Dr Andrew Hall et al.	The V617F mutation in Jak2 is not found in childhood acute lymphoblastic leukaemia	2005
Dr Mark Velangi Elizabeth Matheson Dr Penelope Taylor Professor Graham Jackson Dr Andrew Hall et al.	BRAF gene is not mutated in mismatch repair-proficient or -deficient plasma cell dyscrasias	2004
Dr Mark Velangi Elizabeth Matheson Professor Graham Jackson Dr Penelope Taylor Dr Andrew Hall et al.	DNA mismatch repair pathway defects in the pathogenesis and evolution of myeloma	2004
Dr Andrew Hall Professor Julie Irving Lynne Minto	Genetic variants of ataxia telangiectasia mutated (ATM) and susceptibility for childhood T-lineage acute lymphoblastic leukemia.	2004
Dr Andrew Hall Clare Bloodworth Dr Linda Hogarth Dr Nicholas Bown Professor Julie Irving et al.	Loss of heterozygosity in childhood acute lymphoblastic leukaemia detected by genome-wide microarray single nucleotide polymorphism analysis	2004
Dr Akheel Syed Professor Julie Irving Dr Chris Redfern Dr Andrew Hall Professor Nigel Unwin et al.	Low Prevalence of the N363S Polymorphism of the Glucocorticoid Receptor in South Asians Living in the United Kingdom	2004
Professor Julie Irving Professor Stephen O'Brien Dr Anne Lennard Lynne Minto Dr Feng Lin et al.	Use of Denaturing HPLC for Detection of Mutations in the BCR-ABL Kinase Domain in Patients Resistant to Imatinib	2004
Dr Mark Velangi Professor Graham Jackson Dr Penelope Taylor Dr Andrew Hall Professor Julie Irving et al.	DNA mismatch repair pathway defects in the pathogenesis and evolution of myeloma	2003
Dr Andrew Hall Dr Sally Coulthard Professor Julie Irving	Molecular diagnostics: a healthcare perspective	2003
Professor Julie Irving Professor Stephen O'Brien Dr Anne Lennard Dr Feng Lin Dr Andrew Hall et al.	The use of denaturing high-performance liquid chromatography (DHPLC) for the detection of mutations in the bcr-abl oncogene in patients resistant to imatinib	2003
Diana Levett Dr Andrew Hall Dr John Hanley Professor Julie Irving	Comparitive study of conformation sensitive gel electrophoresis (CSGE) and denaturing high pressure liquid chromatography (DHPLC) for mutation detection in von Willebrands disease	2002
Dr Andrew Hall Professor Julie Irving	New drugs, new drug resistance mechanisms	2002
Professor Julie Irving Dr Andrew Hall	Mismatch repair defects as a cause of resistance to cytotoxic drugs	2001
Professor Julie Irving Dr Penelope Taylor Professor Graham Jackson Dr Andrew Hall	The presence of mismatch repair defects in plasma cell dyscrasias	2001
Professor Julie Irving Dr Anne Lennard Professor Stephen Proctor Dr Penelope Taylor	Validation of the Hasford score in a demographic study in chronic granulocytic leukaemia	2001
Dr Peter Middleton Jean Norden Diana Levett Dr Mark Levasseur Professor Julie Irving et al.	Population-based study of the pattern of molecular markers of minimal residual disease in childhood and adult acute lymphoblastic leukemia: An assessment of the practical difficulty of representative sampling for trial purposes	2000
Professor Julie Irving Gerard Cain Dr Brian Angus Dr Penelope Taylor	The role of alternative splicing of the adhesion molecule, CD44, in lymphoid malignancy	1998
Professor Julie Irving Dr Anne Lennard Professor Anne Dickinson	Philadelphia evaluations of CD34 populations in chronic granulocytic leukaemia; A comparison of bone marrow and peripheral blood stem cell harvests.	1997
Professor Julie Irving Gerard Cain Dr Brian Angus	The role of alternative splicing of the adhesion molecule, CD44 in lymphoid malignancy	1997
Professor Julie Irving Gerard Cain Dr Brian Angus	OCT embedded sections of pathological specimens as a source of high quality RNA for reverse transcriptase/polymerase chain reaction	1996
Professor Julie Irving Professor Stephen Proctor Professor Graham Jackson	Basophilia, t(15;17) translocation and atypical AML	1995
Professor Julie Irving	A simple, reproducible and cheap batch method for the analysis of serum glycoproteins using sepharose-coupled lectins and silver staining	1987